Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG
Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG
Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
52 Management <strong>Report</strong> Konzernlagebericht<br />
Liquidity risks and risks from cash flow fluctuations<br />
The risk of a short-term liquidity shortage is observed by the management via liquidity monitoring.<br />
Therefore, the maturity of financial assets, especially accounts receivable and accounts payable as well<br />
as the expected operating cash flow are considered.<br />
Due to the momentary available liquidity together with the projected medium-term capital requirements<br />
the Executive Board sees no risks. There is a general risk of cash flow fluctuations, especially in<br />
cases of unexpected outcomes of legal disputes or due to unexpected negative changes on key markets.<br />
However, the Executive Board is convinced that even in such cases the disposable financial assets<br />
are sufficient to counter-balance such cash flow fluctuations and therefore sees no further risks.<br />
Investment risks<br />
Some of the subsidiaries’ existence is dependent on financing by the parent company or other subsidiaries.<br />
Especially the distribution company in the USA is refinanced this way. The net lendings/net borrowings<br />
of the group’s companies value in different currencies – often not even in functional currencies<br />
– and therefore a risk of currency conversions can be observed.<br />
A disclosure on the group’s legal risks can be found in the notes’ section “Process and Legal risks.”<br />
Anticipated company development<br />
Taking into account the aforementioned projected chances and risks, a positive business performance<br />
can be expected during the next two years. This evaluation is made under the premise that the market<br />
penetration of <strong>biolitec</strong>’s products can be increased through intensified distribution activities, the production<br />
related processes are optimized according to the developing technological standard as well as<br />
no unexpected legal disputes arise.<br />
Explanatory <strong>Report</strong> by the Executive Board on the pursuant to<br />
§§ 289 V, 315 II No. 5 of the German Commercial Code (HGB)<br />
Legal Background<br />
The Accounting Law Reform Act (BilMoG) enacted 29 May <strong>2009</strong> amended §§289, 315 of the German<br />
Commercial Code (Handelsgesetzbuch, HGB) and §§120, 175 German Stock Corporation Act<br />
(Aktiengesetz,AktG). Pursuant to the Reform Act, the Executive Board must present a written report to<br />
shareholders at the <strong>Annual</strong> General Meeting on matters including the new disclosure requirements in<br />
the management report per §289 V HGB and in the Group management report per §315 II No. 5 HGB<br />
regarding the internal control and risk management system in place for the accounting and consolidated<br />
accounting process.<br />
In the later German Act Implementing the Shareholders’ Rights Directive (Gesetz zur Umsetzung der<br />
Aktionärsrichtlinie – ARUG) legislators bundled requirements for providing explanatory reports under §<br />
176 I Sentence 1 AktG and eliminated the previous regulations under §120 III Sentence 2 and §175 II<br />
Sentence 1 AktG. The reference to §289 V HGB added by BilMoG and the management report disclosures<br />
on the internal control and risk management system in place for the accounting and consolidated<br />
accounting process were not incorporated. On the other hand, the German Department of Justice